

Appendix 1. List of the Included Studies

- A1. Liu X, Lin H, Jiang H, Li R, Zhong N, Su H, et al. Clinical characteristics of hospitalised patients with schizophrenia who were suspected to have coronavirus disease (COVID-19) in Hubei Province, China. *Gen Psychiatr.* 2020;33(2):e100222.
- A2. Ma J, Hua T, Zeng K, Zhong B, Wang G, Liu X. Influence of social isolation caused by coronavirus disease 2019 (COVID-19) on the psychological characteristics of hospitalized schizophrenia patients: a case-control study. *Transl Psychiatry.* 2020;10(1):411.
- A3. Zeng L, Zhang H, He Y, Lai B, Huang Z, Lin L, et al. A severe COVID-19 case with schizophrenia as well as other chronic diseases. *Braz J Med Biol Res.* 2021;54(3):e10426.
- A4. Ma J, Jiang T, Huang H, Li R, Zhang L, Liu L, et al. Mental symptoms and stress of hospitalized schizophrenia patients with 2019 novel coronavirus disease: an observation study. *Front Psychiatry.* 2021;12:557611.
- A5. Escolà-Gascón Á. Impact of conspiracist ideation and psychotic-like experiences in patients with schizophrenia during the COVID-19 crisis. *Journal of Psychiatric Research.* 2022; 146:135-148.
- A6. Kikutani T, Ichikawa Y, Kitazume E, Mizukoshi A, Tohara T, Takahashi N, et al. COVID-19 infection-related weight loss decreases eating/swallowing function in schizophrenic patients. *Nutrients.* 2021;13(4).
- A7. Llesuy JR, Sidelnik SA. Death from COVID-19 in a patient receiving clozapine: factors involved and prevention strategies to consider. *Prim Care Companion CNS Disord.* 2020;22(4).
- A8. Tzur Bitan D, Kridin K, Cohen AD, Weinstein O. COVID-19 hospitalisation, mortality, vaccination, and postvaccination trends among people with schizophrenia in Israel: a longitudinal cohort study. *Lancet Psychiatry.* 2021;8(10):901-908.
- A9. Tzur Bitan D, Krieger I, Kridin K, Komantscher D, Scheinman Y, Weinstein O, et al. COVID-19 Prevalence and Mortality Among Schizophrenia Patients: A Large-Scale Retrospective Cohort Study. *Schizophr Bull.* 2021;47(5):1211-1217.
- A10. Fond G, Pauly V, Leone M, Llorca PM, Orleans V, Loundou A, et al. Disparities in intensive care unit admission and mortality among patients with schizophrenia and COVID-19: A national cohort study. *Schizophr Bull.* 2021;47(3):624-634.
- A11. Fond G, Pauly V, Orleans V, Antonini F, Fabre C, Sanz M, et al. Increased in-hospital mortality from COVID-19 in patients with schizophrenia. *Encephale.* 2021;47(2):89-95.
- A12. Kotlarska K, Wielgus B, Cichocki Ł. Phenomenology of the COVID-19 pandemic experience in patients suffering from chronic schizophrenia - a qualitative analysis. *International Journal of Environmental Research and Public Health.* 2022; 19(1).
- A13. Civan Kahve A, Kaya H, Darben Y, Gul Cakil A, Goka E. From predictions to evidence: Treatment compliance, disease progression and social compliance of patients with schizophrenia in the COVID-19 pandemic. *Perspective in Psychiatric Care.* 2021;57(4):1991-1998.
- A14. Kisely S, Dangelo-Kemp D, Taylor M, Liu D, Graham S, Hartmann J, et al. The impact of COVID-19 on antipsychotic prescriptions for patients with schizophrenia in Australia. *Australian & New Zealand Journal of Psychiatry.* 2021;486742110 25716.
- A15. Moga S, Teodorescu A, Ifteni P, Gavris C, Petric PS. Inflammatory response in SARS-CoV-2 infection of patients with schizophrenia and long-term antipsychotic treatment. *Neuropsychiatric Disease and Treatment.* 2021;17:3053-3060.